Gefapixant 100 mg

Phase 2

MERCK (MRK)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Apr '27

MRKPhase 3$364.4B

Placebo Phase 3 Est. Readout

Gefapixant 100 mg• Refractory Chronic Cough250

Apr 2027~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Refractory Chronic Cough

GSKcamlipixant

Phase 3

View Full Landscape

Drug Information

Target Indication

Refractory Chronic Cough

Clinical Trial

NCT02476890

Last updated: 1/1/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MK-8748Phase 3

Diabetic Retinopathy

alendronate with cholecalciferolPhase 3

Osteoporosis

Simvastatin 20 mg dailyPhase 3

Cardiovascular Disease

EpinephrinePhase 3

Malignant Neoplasms of Male Genital Organs

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3

HPV Positive Oropharyngeal Squamous Cell Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts